Signed Aug 30, 2022
- Committed
- $150m
- Matures
- Aug 2029
- Agent
- Not stated
| Tranche | Size | Matures | Margin |
|---|---|---|---|
| 6.42% Series A Senior Notes | $50m | Aug 2029 | n/a |
| 6.50% Series B Senior Notes | $75m | Aug 2032 | n/a |
| 6.75% Series C Senior Notes | $25m | Aug 2034 | n/a |
NOTE PURCHASE AGREEMENT
CovenantTestedHeadroomLimit now
Tested quarterlyHeadroom not yet measured3.50x
Equity cure available.
The Company will not permit the ratio of (i) Consolidated Net Funded Indebtedness as of the end of any fiscal quarter of the Company to (ii) Consolidated Adjusted EBITDA (such ratio, the “Consolidated Net Leverage Ratio”) for the period of four consecutive fiscal quarters ended on such date to be greater than 3.50 to 1.00Read the filing on sec.gov ↗
Tested quarterlyHeadroom not yet measured10,616,900,000
The Company will not permit, as of the end of any fiscal quarter, the Fee Earning Equity Owned and Operated to be less than $10,616,900,000.Read the filing on sec.gov ↗
Amendments
No amendments on file yet.
Report an error
Email [email protected].